Literature DB >> 27162032

Simultaneous His Bundle and Left Ventricular Pacing for Optimal Cardiac Resynchronization Therapy Delivery: Acute Hemodynamic Assessment by Pressure-Volume Loops.

Luigi Padeletti1, Paolo Pieragnoli2, Giuseppe Ricciardi2, Lisa Innocenti2, Luca Checchi2, Margherita Padeletti2, Antonio Michelucci2, Francesco Picariello2, Sergio Valsecchi2.   

Abstract

BACKGROUND: Previous studies have investigated the role of intrinsic conduction in optimizing cardiac resynchronization therapy. We investigated the role of fusing pacing-induced activation and intrinsic conduction in cardiac resynchronization therapy by evaluating the acute hemodynamic effects of simultaneous His-bundle (HIS) and left ventricular (LV) pacing. METHODS AND
RESULTS: We studied 11 patients with systolic heart failure and left bundle-branch block scheduled for cardiac resynchronization therapy implantation. On implantation, LV pressure-volume data were determined via conductance catheter. Standard leads were placed in the right atrium, at the right ventricular apex, and in a coronary vein. An additional electrode was temporarily positioned in the HIS. The following pacing configurations were systematically assessed: standard biventricular (right ventricular apex+LV), LV-only, HIS, simultaneous HIS and LV (HIS+LV). Each configuration was compared with the AAI mode at multiple atrioventricular delays (AVD). In comparison with the AAI, right ventricular apex+LV and LV-only pacing resulted in improved stroke volume (85±32 mL and 86±33 mL versus 58±23 mL; P<0.001), stroke work, maximum pressure derivative, and systolic dyssynchrony at individually optimized AVD. The optimal AVD was close to the P-H interval in the majority of patients. By contrast, HIS-LV pacing improved hemodynamic indexes at all AVD (stroke volume >76 mL at all fixed intervals and 88±31 mL at optimal interval; all P<0.001).
CONCLUSIONS: Standard right ventricular apex+LV and LV-only pacing enhanced systolic function and LV synchrony at individually optimized AVD close to the measured intrinsic P-H interval. By contrast, HIS+LV pacing yielded improvements, regardless of AVD setting. These findings support the hypothesis of the crucial role of intrinsic right ventricular conduction in optimal cardiac resynchronization therapy delivery.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  CRT; His bundle; fusion; heart failure; pressure volume loop; resynchronization

Mesh:

Year:  2016        PMID: 27162032     DOI: 10.1161/CIRCEP.115.003793

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  6 in total

Review 1.  His bundle pacing.

Authors:  Jason Payne; Ann C Garlitski; Jonathan Weinstock; Munther Homoud; Christopher Madias; N A Mark Estes
Journal:  J Interv Card Electrophysiol       Date:  2018-08-13       Impact factor: 1.900

Review 2.  Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation?

Authors:  Zak Loring; Albert Y Sun
Journal:  Cardiol Clin       Date:  2019-02-10       Impact factor: 2.213

Review 3.  Device Programming for His Bundle Pacing.

Authors:  Haran Burri; Daniel Keene; Zachary Whinnett; Francesco Zanon; Pugazhendhi Vijayaraman
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-02

4.  Leadless Left Bundle Branch Area Pacing in Cardiac Resynchronisation Therapy: Advances, Challenges and Future Directions.

Authors:  Nadeev Wijesuriya; Mark K Elliott; Vishal Mehta; Baldeep S Sidhu; Marina Strocchi; Jonathan M Behar; Steven Niederer; Christopher A Rinaldi
Journal:  Front Physiol       Date:  2022-06-06       Impact factor: 4.755

5.  Acute torrential mitral regurgitation during transcatheter aortic valve replacement: a case report.

Authors:  Yoshiyuki Yamashita; Hiromichi Sonoda; Tomoki Ushijima; Akira Shiose
Journal:  Surg Case Rep       Date:  2018-04-18

Review 6.  Alternative pacing strategies for optimal cardiac resynchronization therapy.

Authors:  Juan Hua; Qiling Kong; Qi Chen
Journal:  Front Cardiovasc Med       Date:  2022-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.